AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca Launches Early Scan Study in Targeted Lung Cancer
The phase I study, A Phase I Multicentre Open-label Study to Evaluate Safety, Tolerability, and Dosimetry of [111In]-FPI-2107 in Chinese Adult Participants With EGFR Mutation-positive NSCLC, tests a new scan agent in a narrow lung cancer group. It aims to see if this tool is safe and useful for tracking tumors, which could improve care in a key oncology market.
The trial uses two related drugs. [111In]-FPI-2107 is an injected imaging agent, while FPI-2053 is a paired antibody dose given first to guide how the tracer targets cancer cells.
This is an interventional study with one group and no placebo. All patients get the same treatment, and the trial is open label, meaning doctors and patients know what is given, with the main goal to support diagnosis rather than direct treatment.
The trial was first submitted on 18 Feb 2026, marking the formal start of the clinical path. The latest update on 21 Apr 2026 shows the plan is active and the design is still current while the team is recruiting patients.
For investors, this update reinforces AstraZeneca’s push in precision lung cancer tools, which can support its broader EGFR drug line and defend share against rivals like Roche and Novartis. While phase I imaging data will not move earnings near term, steady progress can support sentiment around AZN’s oncology pipeline and its positioning in China.
The study remains in the recruiting stage with recent updates, and more details are available on the ClinicalTrials portal.
To learn more about GB:AZN’s potential, visit the AstraZeneca plc drug pipeline page.